CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)

NCT ID: NCT07165678

Last Updated: 2025-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-30

Study Completion Date

2028-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate whether a coronary computed tomography angiography (CTCA)-guided strategy can reduce the risk of death, heart attack, stroke, and hospital admissions in patients experiencing angina or myocardial infarction following coronary artery bypass graft (CABG) surgery. The main questions it aims to answer are:

* Can CTCA reduce major adverse cardiovascular events compared to standard invasive coronary angiography?
* Is CTCA a cost-effective and safer alternative that improves patient quality of life? Researchers will compare outcomes between patients receiving CTCA prior to angiography and those undergoing standard angiography alone to determine if CTCA improves clinical outcomes and procedural safety.

Participants will:

* Be randomly assigned to either CTCA-guided care or standard angiography
* Undergo coronary imaging and follow-up assessments
* Complete questionnaires on quality of life and healthcare resource use

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with prior coronary artery bypass graft (CABG) surgery frequently present with recurrent angina or acute coronary syndromes due to progressive native coronary artery disease or graft failure. Invasive coronary angiography remains the standard diagnostic approach but is technically challenging in this population due to variable graft anatomy, leading to prolonged procedure times, increased radiation exposure, higher contrast volumes, and elevated risk of procedural complications.

Computed Tomography Coronary Angiography (CTCA) offers a non-invasive alternative with high diagnostic accuracy for graft patency and coronary anatomy. Prior observational data (e.g., BYPASS-CTCA study) suggest that CTCA performed prior to invasive angiography may improve procedural efficiency and safety. However, whether CTCA can guide clinical decision-making to avoid unnecessary angiography and improve long-term outcomes remains unproven.

This multi centre, randomised controlled trial will enrol 1,000 patients with prior CABG presenting with angina or myocardial infarction. Participants will be randomised to either a CTCA-guided strategy or standard care involving direct invasive coronary angiography. In the CTCA arm, angiography may be deferred if CTCA findings support medical management. The primary outcome is the composite rate of major adverse cardiovascular events (MACE), including death, myocardial infarction, stroke, and hospitalisation for unstable angina. Secondary outcomes include procedural metrics, patient-reported quality of life, cost-effectiveness, and healthcare resource utilization.

Clinical data will be collected through patient questionnaires, procedural records, and central registry downloads. The study incorporates patient and public involvement throughout its design and implementation. Results will be disseminated via peer-reviewed publications, public-facing reports, and digital platforms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Arm A: coronary angiography alone Arm B: CTCA scan with or without angiography
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICA only

Invasive coronary angiogram (ICA) performed only.

Group Type NO_INTERVENTION

No interventions assigned to this group

CTCA with or without ICA

Computed Tomography Cardiac Angiography (CTCA) with or without invasive coronary angiogram (ICA)

Group Type ACTIVE_COMPARATOR

CTCA

Intervention Type DIAGNOSTIC_TEST

Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTCA

Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Computed Tomography Cardiac angiography

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged ≥18
* Previous coronary artery bypass grafting (CABG)
* An indication for coronary angiography

* Angina
* Ischaemia on perfusion imaging
* Acute coronary syndrome
* Patients are able and willing to give their written informed consent

Exclusion Criteria

* Subjects presenting with ST segment myocardial infarction within window for primary PCI
* Patients considered unsuitable to participate by the research team (e.g. due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures)
* Life expectancy less than 1 year
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute for Health Research, United Kingdom

OTHER_GOV

Sponsor Role collaborator

Queen Mary University of London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel Jones, MRCP, PhD

Role: PRINCIPAL_INVESTIGATOR

Queen Mary University of London

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mervyn Andiapen

Role: CONTACT

0203 765 8707

Matthew Kelham, MBBS, MD

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIHR207209

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

PR2300245

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

341412

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Angiosome Perfusion After Tibial Bypass
NCT03012750 COMPLETED PHASE2
BMAC Enhanced Coronary Artery Bypass Grafting (CABG)
NCT01061580 TERMINATED PHASE1/PHASE2